The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Trodelvy has already crossed the blockbuster threshold for Gilead, with sales rising 24% to $1.3 billion last year, although, Gilead's attempts to extend its use into other cancers have had mixed ...

However, softness in oncology—particularly Trodelvy—and ongoing challenges in the cell therapy segment weighed on overall results. CEO Daniel O’Day acknowledged, “Year-over-year g.

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt ; Innovative partnership enables Revolution Medicines to retain control over pipeline ...